MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03721016
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
415
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Lines
Lateral Canthal Lines
Interventions
DRUG:
MT10109L
DRUG:
Placebo
Sponsor
Medy-Tox